A Phase I/II study to evaluate AZD5851 in GPC3+ advanced/recurrent hepatocellular carcinoma - ATHENA

Study identifier:D7670C00001

ClinicalTrials.gov identifier:NCT06084884

EudraCT identifier:N/A

CTIS identifier:N/A

Recruiting

Official Title

A Phase I/II Open-Label Study to Evaluate the Safety, Cellular Kinetics and Efficacy of AZD5851, a Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Directed Against GPC3 in Adult Participants With Advanced/Recurrent Hepatocellular Carcinoma: ATHENA

Medical condition

Hepatocellular Carcinoma

Phase

Phase 1/2

Healthy volunteers

No

Study drug

-

Sex

All

Estimated Enrollment

84

Study type

Interventional

Age

18 Years - 130 Years

Date

Study Start Date: 27 Nov 2023
Estimated Primary Completion Date: 13 Dec 2027
Estimated Study Completion Date: 13 Dec 2027

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 May 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria